People | December 09, 2022
Lupin appoints Spiro Gavaris as President of U.S. Generics Business
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Diana is a senior leader with more than 38 years of field experience in U.S. FDA’s Office of Regulatory Affairs (ORA)
The initiative brings internationally eminent cardiologists to increase awareness of health screening tests amongst pre-menopausal women
He will continue to lead business in LATAM and Asia regions in this new role
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
FDA changes inspection classification of the facility to Voluntary Action Indicated
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Subscribe To Our Newsletter & Stay Updated
